David McClung's most recent trade in BioCardia Inc. was a trade of 4,819 Warrant (right to buy) done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioCardia Inc. | David McClung | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 30 Jun 2025 | 4,819 | 26,275 | - | - | Warrant (right to buy) | |
| BioCardia Inc. | David McClung | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.07 per share. | 30 Jun 2025 | 4,819 | 47,950 (0%) | 0% | 2.1 | 9,999 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 23 Apr 2025 | 13,123 | 21,456 | - | - | Warrant (right to buy) | |
| BioCardia Inc. | David McClung | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.90 per share. | 23 Apr 2025 | 13,123 | 43,131 (0%) | 0% | 1.9 | 24,999 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 2.65 per share. | 11 Oct 2024 | 24,193 | 41,573 (0%) | 0% | 2.6 | 64,111 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.65 per share. | 11 Oct 2024 | 11,565 | 30,008 (0%) | 0% | 2.6 | 30,647 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 3.00 per share. | 03 Sep 2024 | 8,333 | 17,380 (0%) | 0% | 3 | 24,999 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Sep 2024 | 8,333 | 8,333 | - | - | Warrant (right to buy) | |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.77 per share. | 25 Aug 2023 | 1,925 | 214,396 (0%) | 0% | 0.8 | 1,482 | Common Stock |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.19 per share. | 25 Jun 2023 | 11,528 | 211,321 (0%) | 0% | 1.2 | 13,718 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 2.34 per share. | 23 Jun 2023 | 4,280 | 135,724 (1%) | 0% | 2.3 | 9,998 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.77 per share. | 31 May 2023 | 20,676 | 131,444 (1%) | 0% | 1.8 | 36,597 | Common Stock |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.33 per share. | 25 May 2023 | 1,925 | 222,849 (0%) | 0% | 1.3 | 2,560 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2023 | 68,265 | 68,265 | - | - | Stock Option (right to buy) | |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.70 per share. | 18 May 2023 | 61,389 | 152,120 (2%) | 0% | 1.7 | 104,361 | Common Stock |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 262,500 | 262,500 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2023 | 56,250 | 234,519 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.66 per share. | 24 Feb 2023 | 9,745 | 224,774 (0%) | 0% | 2.7 | 25,922 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.68 per share. | 16 Dec 2022 | 8,928 | 87,446 (1%) | 0% | 1.7 | 14,999 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.07 per share. | 10 Oct 2022 | 2,000 | 78,518 (1%) | 0% | 2.1 | 4,140 | Common Stock |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.31 per share. | 25 Jun 2022 | 11,525 | 175,816 (0%) | 0% | 4.3 | 49,673 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.32 per share. | 12 May 2022 | 20,632 | 76,518 (1%) | 0% | 1.3 | 27,234 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2022 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2022 | 50,345 | 97,150 (1%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 160,380 | 160,380 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 59,400 | 184,984 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.90 per share. | 25 Feb 2022 | 4,610 | 125,584 (0%) | 0% | 5.9 | 27,199 | Common Stock |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.02 per share. | 25 Jun 2021 | 11,525 | 129,294 (0%) | 0% | 12.0 | 138,531 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.35 per share. | 10 Jun 2021 | 7,274 | 46,805 (0%) | 0% | 4.4 | 31,642 | Common Stock |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2021 | 75,850 | 75,850 | - | - | Stock Option (right to buy) | |
| BioCardia Inc. | David McClung | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2021 | 21,370 | 54,079 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Sangamo Therapeutics Inc | David Mark McClung | EVP, Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 40,000 | 140,000 (0%) | 0% | 0 | Common Stock |